Farrag MA, Amer HM, Bhat R, Hamed ME, Aziz IM, Mubarak A, et al. SARS-CoV-2: An Overview of Virus Genetics, Transmission, and Immunopathogenesis. Int J Environ Res Public Health. 2021. 18.

Harder T, Kulper-Schiek W, Reda S, Treskova-Schwarzbach M, Koch J, Vygen-Bonnet S, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. Euro Surveill. 2021. 26.

Kanamori H. An overview of research on air and environmental contamination with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in healthcare settings. Infect Control Hosp Epidemiol. 2020: 1-4.

Kim Y, Kim EJ, Lee SW, Kwon D. Review of the early reports of the epidemiological characteristics of the B.1.1.7 variant of SARS-CoV-2 and its spread worldwide. Osong Public Health Res Perspect. 2021. 12: 139-148.

Kumar M, Kumari N, Thakur N, Bhatia SK, Saratale GD, Ghodake G, et al. A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics. Plants (Basel). 2021. 10.

Li P, Zhang J, Lin Q, Kong J. Rapid differential diagnosis of the B.1.617.2 (delta) variant of SARS-CoV-2 using an automated Cas12a-microfluidic system. Chem Commun (Camb). 2021. 57: 12270-12272.

Mutnal MB, Johnson S, Mohamed N, Abdelgader R, Morales L, Volz M, et al. Surveillance genome sequencing reveals multiple SARS-CoV-2 variants circulating in central Texas, USA, with a predominance of delta variant and review of vaccine breakthrough cases. J Med Virol. 2021.

Alnagreh L, Ababneh M, Al-Shudifat AE, Ajlouny M, Abu - Shaikh H, Alzouqhoul F, et al. New SARS-CoV-2 Variant from Jordan. Microbiol Resour Announc. 2021. 10: e0053221.

Fillatre P, Dufour MJ, Beilhill S, Vatan R, Reusse P, Gabellec A, et al. A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study. Clin Microbiol Infect. 2021.

Paniri A, Hosseini MM, Akhavan-Niaki H. Impact of new UK (B.1.1.7) SARS-CoV-2 variant on interacting with ACE2 and host immune response. Gene Rep. 2021. 25: 101342.

Poulves KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Kitch KD, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021.

Zalona Fernandes HM, Miranda KR, da Silva Dias RC, Alviano DS, Duarte RS, da Silva LMC, et al. The challenges of elucidating the interaction between SARS-CoV-2 variants and vaccines: a systematic review. Hum Vaccin Immunother. 2021.

Cheng C, Wang L, Lyu Z, Peng B, Li Y, Kong D, et al. Four COVID-19 Cases of New Variant B.1.351 First Emerging in South Africa in Chinese Passengers on Same Flight - Shenzhen, China, January 2021. China CDC Wkly. 2021. 3: 175-177.

Linka K, Peirlinck M, Schafer A, Thiruvengadam J, Oz G, Goriely A, Kuhl E. Effects of B.1.1.7 and B.1.351 on COVID-19 Dynamics: A Campus Reopening Study. Arch Comput Methods Eng. 2021: 1-12.

Abe H, Ushijima Y, Bikangui R, Zoa-Assoumou S, Ondo GN, Manouana GP, et al. Unrecognized introduction of SARS-CoV-2 variants of concern to Central Africa: Import and local transmission of B.1.1.7 in Gabon in the very early stage of the variant spread to the African continent. J Med Virol. 2021. 93: 6054-6058.

Jaspe RC, Loureiro CL, Subaran Y, Moros C6, D’Angelo P, Rodriguez L, et al. Introduction and rapid dissemination of SARS-CoV-2 Gamma Variant of Concern in Venezuela. Infect Genet Evol. 2021. 96: 105117.

Novazzi F, Genoni A, Spezia PG, Focosi D, Zago C, Colombo A, et al. Introduction of SARS-CoV-2 variant of concern 20H/501Y.V2 (B.1.351) from Malawi to Italy. Emerg Microbes Infect. 2021. 10: 710-712.

Sallam M, Mahafzah A. Molecular Analysis of SARS-CoV-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level. Pathogens. 2021. 10.

Eyal N, Caplan AL. Bioethics in COVID vaccine trials: The B.1.351 (“South African”) variant - the urgent need to lay the groundwork for possible future challenge studies. Hum Vaccin Immunother. 2021: 1-12.

Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Vaccine against SARS-CoV-2. N Engl J Med. 2021. 385: 1859-1869.

Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021. 384: 1899-1909.

Armstrong PM, Andreadis TG. A new genetic variant of La Crosse virus (bunyaviridae) isolated from New England. Am J Trop Med Hyg. 2006. 75: 491-6.

Grint DJ, Wing K, Houlihan C, Gibbs HP, Evans SJW, Williamson E, et al. Severity of SARS-CoV-2 alpha variant (B.1.1.7) in England. Clin Infect Dis. 2021.

Williams SV, Vusirikala A, Ladhani SN, Fernandez Ruiz De Olano E, Iyanger R, Aiano F, et al. An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021. Euro Surveill. 2021. 26.

Collier DA, De Marco A, Ferreira I, Meng B, Datir R, Walls AC, et al. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. medRxiv. 2021.

Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021. 593: 136-141.

Bugembe DL, Phan MVT, Ssewanyana I, Semand P, Nansumba H, Dhaala B, et al. Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda. Nat Microbiol. 2021. 6: 1094-1101.

Dudas G, Hong SL, Potter BI, Calvignac-Spencer S, Niatou-Singa FS, Tombolomako TB, et al. Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions. Nat Commun. 2021. 12: 5769.

Baj A, Novazzi F, Pasciuta R, Genoni A, Ferrante FD, Valli M, et al. Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy. Emerg Infect Dis. 2021. 27: 3180-3182.

Jensen B, Luebke N, Feldt T, Keitel V, Brandenburg T, Kindgen-Milles D, et al. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Reg Health Eur. 2021. 8: 100164.

Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021. 372: 815-821.

Tchesnokova V, Kulasekara H, Larson L, Bowers V, Rechkina E, Kisiela D, et al. Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants. J Clin Microbiol. 2021. 59: e0092121.

Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe. 2021. 29: 1124-1136 e11.

Gazali FM, Nuhamanaad M, Nabilla R, Supriyati E, Hakim MS, Arguni E, et al. Detection of SARS-CoV-2 spike protein D614G mutation by qPCR-HRM analysis. Heliyon. 2021. 7: e07936.

McAuley AJ, Kuiper MJ, Durr PA, Bruce MP, Barr J, Todd S, et al. Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. NPJ Vaccines. 2020. 5: 96.

Yang TJ, Yu PY, Chang YC, Hsu SD. D614G mutation in the SARS-CoV-2 spike protein enhances viral fitness by desensitizing it to temperature - dependent denaturation. J Biol Chem. 2021. 297: 101232.